When the FDA Pharmacy Compounding Advisory Committee concluded its July 23 and 24, 2026 meeting, it generated significant discussion among physicians, researchers, compounding pharmacies, and patients interested in peptide therapy.
With so much conflicting information circulating online, we are here to provide a direct and accurate explanation of what happened during the meeting, what the committee’s recommendations actually mean, and what must occur before any regulatory changes can take effect.
Contents
FDA Advisory Committee Recommends Six of Seven Peptides
During the two day meeting, the FDA Pharmacy Compounding Advisory Committee reviewed seven investigational peptide substances nominated for possible inclusion on the Section 503A Bulks List.
The substances have attracted research interest in areas such as tissue repair, inflammatory response, metabolic and mitochondrial health, sleep, healthy aging, and neurological health. However, these areas of interest should not be interpreted as proven benefits or FDA approved uses.
After considering FDA presentations, available scientific evidence, and public testimony, the committee recommended six of the seven substances for possible inclusion on the list. Several votes were close, highlighting continued questions about the available evidence, product quality, patient safety, and appropriate medical oversight. The recommendations are an important step in the review process, but they did not approve the substances, authorize their immediate use in compounding, or change current regulatory requirements.
What Is the Section 503A Bulks List?
Section 503A of the Federal Food, Drug, and Cosmetic Act establishes requirements for traditional compounding pharmacies that prepare patient specific medications pursuant to valid prescriptions. When a bulk drug substance is not covered by an applicable United States Pharmacopeia or National Formulary monograph and is not a component of an FDA approved medication, it generally must appear on the 503A Bulks List to qualify for use in compounding under this pathway. The advisory committee’s responsibility was to evaluate the available information and provide recommendations to the FDA. The FDA retains the authority to determine whether any of the reviewed substances will ultimately be added to the list.
FDA Approval Versus Permitted Compounding
One of the biggest misconceptions following the meeting is that the reviewed peptides became FDA approved. That is not what occurred. FDA approval means the agency has reviewed a specific manufactured drug product, including its formulation, intended use, supporting evidence, manufacturing process, and labeling.
Placement on the 503A Bulks List is different. It may provide a pathway for appropriately licensed compounding pharmacies to prepare patient specific medications when all applicable federal, state, pharmacy, prescribing, and clinical requirements are satisfied. Even if a reviewed substance is eventually added to the list, a compounded medication prepared from that substance would not become an FDA approved drug or carry an FDA approved indication.
The fact that a compounded medication is not FDA approved does not automatically mean it is unsafe. However, quality and safety cannot be assumed. They depend heavily on appropriate prescribing, lawful compounding, ingredient sourcing, pharmacy standards, quality testing, storage, and clinical oversight. At Fountain of You MD, we carefully evaluate our pharmacy partners and the medications they prepare before incorporating compounded treatments into patient care.
What This Means for Our Patients
At Fountain of You MD, we are closely following these developments while preparing responsibly for the possibility that additional peptide therapies may become lawfully available through appropriately licensed compounding pharmacies.
If additional peptides become eligible for patient specific compounding, our medical team will evaluate each therapy carefully before determining whether it belongs in patient care. This evaluation will include:
- Confirming that the current regulatory pathway permits its use
- Verifying that it comes from an acceptable, licensed source
- Reviewing available product quality documentation
- Evaluating the available evidence, uncertainties, and potential risks
- Developing appropriate protocols for patient education and monitoring
- Determining whether it may be appropriate for an individual patient
- Completing appropriate patient education and informed consent
A change in regulatory status would not mean that every therapy is appropriate for every patient. Treatment decisions would continue to require an individualized medical evaluation and ongoing clinical oversight.
What sets our approach apart is the direct involvement of Dr. Arbuckle. Before Fountain of You MD adopts a new therapy, he personally studies the available research, reviews its clinical and regulatory considerations, evaluates product quality, and carefully assesses the therapy before deciding whether it meets our standards for patient care. We do not add treatments simply because they are new, popular, or widely discussed.
We will not prescribe or administer products labeled solely for research use or represent investigational substances as FDA approved therapies. A change in regulatory status would not mean that every therapy is appropriate for every patient. Treatment decisions would continue to require an individualized medical evaluation and ongoing clinical oversight.
What Happens Next?
The FDA will consider the advisory committee’s recommendations alongside the complete scientific and regulatory record. If the agency decides to move forward, it would generally begin a formal rulemaking process. This may include publication of a proposed rule, a public comment period, review of stakeholder feedback, and consideration of a final rule.
The FDA is not required to adopt the committee’s recommendations, and no official timeline has been established for a final decision. It may take several months or longer. Until that process is completed, the regulatory status of the reviewed substances remains unchanged.
Frequently Asked Questions
Did the FDA approve these peptides in the July 23 and 24, 2026 meeting?
No. The advisory committee issued recommendations regarding possible inclusion on the 503A Bulks List. The FDA did not approve the reviewed substances as medications.
Can the reviewed substances be prescribed or compounded now?
The committee’s votes did not create immediate availability. Current federal and state requirements continue to apply while the FDA considers its next steps.
How long could the process take?
Additional FDA review and formal rulemaking may take many months or longer. No official timeline has been announced.
Will Fountain of You MD offer additional peptide therapies?
If future regulations permit patient specific compounding and suitable products become available through qualified, licensed pharmacies, our medical team will evaluate each therapy before deciding whether it is appropriate for patient care at our Virginia Beach and Chesapeake offices.
